| Market Cap | 2.01B 1.73B 1.59B 1.49B 2.8B 190B 2.83B 18.81B 7.35B 92.85B 7.53B 7.37B 321B | P/E Ratio 2026 * |
-6.55x | P/E Ratio 2027 * | -5.36x |
|---|---|---|---|---|---|
| Enterprise Value | 2.01B 1.73B 1.59B 1.49B 2.8B 190B 2.83B 18.81B 7.35B 92.85B 7.53B 7.37B 321B | EV / Sales 2026 * |
48.7x | EV / Sales 2027 * | 54.4x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 31/12/2006 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 14/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 30/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 31/07/2000 |
Robert Chess
CHM | Chairman | 67 | 30/04/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 31/01/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 2.01B | |
| -2.86% | -0.26% | +57.57% | +110.98% | 56.42B | |
| -0.34% | +2.91% | +45.55% | +46.87% | 44.54B | |
| +0.56% | +6.53% | -14.34% | -19.39% | 22.9B | |
| +0.42% | +4.43% | -3.19% | +391.48% | 21.21B | |
| -0.51% | -5.56% | +10.43% | -29.97% | 16.4B | |
| -1.54% | -1.06% | +8.10% | -39.28% | 15.4B | |
| -0.64% | +2.10% | +26.53% | +176.57% | 13.35B | |
| +0.96% | +6.56% | +20.81% | - | 12.36B | |
| +0.32% | +1.60% | +96.37% | +207.56% | 11.15B | |
| Average | -0.43% | +1.66% | +27.54% | +105.60% | 23.75B | |
| Weighted average by Cap. | -0.83% | +2.54% | +32.11% | +98.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.22M 35.53M 32.7M 30.67M 57.62M 3.9B 58.19M 387M 151M 1.91B 155M 151M 6.6B | 36.91M 31.81M 29.28M 27.46M 51.59M 3.49B 52.1M 346M 135M 1.71B 138M 136M 5.91B |
| Net income | -250M -216M -198M -186M -350M -23.63B -353M -2.34B -916M -11.57B -938M -918M -40.04B | -356M -307M -282M -265M -497M -33.62B -502M -3.34B -1.3B -16.47B -1.34B -1.31B -56.98B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
